All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
03Apr17 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Parsortix enables analysis in head and neck cancer
30Mar17 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Prostate Cancer Update
14Feb17 11:39 EQS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Edison issues outlook on Angle
26Jan17 07:01 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Interim Results
04Jan17 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Notice of Results
28Nov16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m ISSUE OF SHARE OPTIONS
24Nov16 14:48 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Result of GM
04Nov16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Barts Research Supports Potential Use of Parsortix
01Nov16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Notice of GM
27Oct16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Director's share purchase
07Oct16 11:57 RNS Legal & General Group 0.88% Various Various Holding(s) in Company
04Oct16 16:35 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Result of AGM
30Sep16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Research published in Clinical Chemistry
19Sep16 11:14 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Issue of Equity
09Sep16 16:12 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Annual Report and Accounts and Notice of AGM
27Jul16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Initiation of 200 patient US ovarian cancer study
19Jul16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Initiation of European ovarian cancer study
15Jul16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Notice of Results
15Jul16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Parsortix gaining traction at EACR Conference
01Jun16 15:04 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Holding(s) in Company
31May16 16:36 RNS Legal & General Group 0.88% Various Various Holding(s) in Company
25May16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Placing
25May16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Cancer Research UK Contract
18Apr16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Parsortix potential in metastatic breast cancer
21Mar16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Parsortix potential for prostate cancer detection
09Mar16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m European patent grant for Parsortix
28Jan16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Interim Results
27Jan16 10:42 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Notice of Interim Results
25Jan16 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m UKE publishes evaluation of Parsortix
22Dec15 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Completion of Geomerics Transaction
15Dec15 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Parsortix first commercial sales
30Nov15 17:56 RNS Angle 19.46% Various Various Holding(s) in Company
17Nov15 07:00 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m Lung Cancer Research Publication
12Nov15 14:17 RNS Angle 19.46% Industrial Equipment, Goods & Services £130.4m ISSUE OF SHARE OPTIONS
Date / Time Source Company % Chg
03Apr17 07:00 RNS Angle 19.46%
Parsortix enables analysis in head and neck cancer
30Mar17 07:00 RNS Angle 19.46%
Prostate Cancer Update
14Feb17 11:39 EQS Angle 19.46%
Edison issues outlook on Angle
26Jan17 07:01 RNS Angle 19.46%
Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 RNS Angle 19.46%
Interim Results
04Jan17 07:00 RNS Angle 19.46%
Notice of Results
28Nov16 07:00 RNS Angle 19.46%
ISSUE OF SHARE OPTIONS
24Nov16 14:48 RNS Angle 19.46%
Result of GM
04Nov16 07:00 RNS Angle 19.46%
Barts Research Supports Potential Use of Parsortix
01Nov16 07:00 RNS Angle 19.46%
Notice of GM
27Oct16 07:00 RNS Angle 19.46%
Director's share purchase
07Oct16 11:57 RNS Legal & General Group 0.88%
Holding(s) in Company
04Oct16 16:35 RNS Angle 19.46%
Result of AGM
30Sep16 07:00 RNS Angle 19.46%
Research published in Clinical Chemistry
19Sep16 11:14 RNS Angle 19.46%
Issue of Equity
09Sep16 16:12 RNS Angle 19.46%
Annual Report and Accounts and Notice of AGM
27Jul16 07:00 RNS Angle 19.46%
Initiation of 200 patient US ovarian cancer study
19Jul16 07:00 RNS Angle 19.46%
Initiation of European ovarian cancer study
15Jul16 07:00 RNS Angle 19.46%
Notice of Results
15Jul16 07:00 RNS Angle 19.46%
Parsortix gaining traction at EACR Conference
01Jun16 15:04 RNS Angle 19.46%
Holding(s) in Company
31May16 16:36 RNS Legal & General Group 0.88%
Holding(s) in Company
25May16 07:00 RNS Angle 19.46%
Placing
25May16 07:00 RNS Angle 19.46%
Cancer Research UK Contract
18Apr16 07:00 RNS Angle 19.46%
Parsortix potential in metastatic breast cancer
21Mar16 07:00 RNS Angle 19.46%
Parsortix potential for prostate cancer detection
09Mar16 07:00 RNS Angle 19.46%
European patent grant for Parsortix
28Jan16 07:00 RNS Angle 19.46%
Interim Results
27Jan16 10:42 RNS Angle 19.46%
Notice of Interim Results
25Jan16 07:00 RNS Angle 19.46%
UKE publishes evaluation of Parsortix
22Dec15 07:00 RNS Angle 19.46%
Completion of Geomerics Transaction
15Dec15 07:00 RNS Angle 19.46%
Parsortix first commercial sales
30Nov15 17:56 RNS Angle 19.46%
Holding(s) in Company
17Nov15 07:00 RNS Angle 19.46%
Lung Cancer Research Publication
12Nov15 14:17 RNS Angle 19.46%
ISSUE OF SHARE OPTIONS
Date / Time Company % Chg
03Apr17 07:00 Angle 19.46%
Parsortix enables analysis in head and neck cancer
30Mar17 07:00 Angle 19.46%
Prostate Cancer Update
14Feb17 11:39 Angle 19.46%
Edison issues outlook on Angle
26Jan17 07:01 Angle 19.46%
Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 Angle 19.46%
Interim Results
04Jan17 07:00 Angle 19.46%
Notice of Results
28Nov16 07:00 Angle 19.46%
ISSUE OF SHARE OPTIONS
24Nov16 14:48 Angle 19.46%
Result of GM
04Nov16 07:00 Angle 19.46%
Barts Research Supports Potential Use of Parsortix
01Nov16 07:00 Angle 19.46%
Notice of GM
27Oct16 07:00 Angle 19.46%
Director's share purchase
07Oct16 11:57 AGL LSE,LGEN LSE 0.88%
Holding(s) in Company
04Oct16 16:35 Angle 19.46%
Result of AGM
30Sep16 07:00 Angle 19.46%
Research published in Clinical Chemistry
19Sep16 11:14 Angle 19.46%
Issue of Equity
09Sep16 16:12 Angle 19.46%
Annual Report and Accounts and Notice of AGM
27Jul16 07:00 Angle 19.46%
Initiation of 200 patient US ovarian cancer study
19Jul16 07:00 Angle 19.46%
Initiation of European ovarian cancer study
15Jul16 07:00 Angle 19.46%
Notice of Results
15Jul16 07:00 Angle 19.46%
Parsortix gaining traction at EACR Conference
01Jun16 15:04 Angle 19.46%
Holding(s) in Company
31May16 16:36 AGL LSE,LGEN LSE 0.88%
Holding(s) in Company
25May16 07:00 Angle 19.46%
Placing
25May16 07:00 Angle 19.46%
Cancer Research UK Contract
18Apr16 07:00 Angle 19.46%
Parsortix potential in metastatic breast cancer
21Mar16 07:00 Angle 19.46%
Parsortix potential for prostate cancer detection
09Mar16 07:00 Angle 19.46%
European patent grant for Parsortix
28Jan16 07:00 Angle 19.46%
Interim Results
27Jan16 10:42 Angle 19.46%
Notice of Interim Results
25Jan16 07:00 Angle 19.46%
UKE publishes evaluation of Parsortix
22Dec15 07:00 Angle 19.46%
Completion of Geomerics Transaction
15Dec15 07:00 Angle 19.46%
Parsortix first commercial sales
30Nov15 17:56 AGL LSE,HGG LSE 19.46%
Holding(s) in Company
17Nov15 07:00 Angle 19.46%
Lung Cancer Research Publication
12Nov15 14:17 Angle 19.46%
ISSUE OF SHARE OPTIONS